Housekeeping in public, as promised: three external events reshaped this market’s facts, and here is exactly what we changed on this site — with sources, dates, and the standing verify-current flag on everything that moves.
Foundayo landed. Orforglipron — the daily small-molecule GLP-1 pill our oral file has tracked since its trial era — was approved in April 2026 under the reported brand name Foundayo, the first approval through FDA’s national priority voucher pathway (FDA announcement). We updated the drug card, the oral file, the homepage timeline, and the trends call it vindicates. A March 19, 2026 approval of higher-dose oral semaglutide (“Wegovy pill”) was reported the same season — both entries carry the same honest asterisk: access, supply, and pricing are still settling, and primary sources outrank us.
Medicare opened a door. The Medicare GLP-1 Bridge — launched July 1, 2026, running through December 2027 per CMS — implements last November’s manufacturer pricing agreements as a reported $50/month coverage lane. We built the full guide: eligibility machinery, covered-drug caveats, the four-step path, and the math against self-pay. If you’re Medicare-enrolled, read that page before any cash checkout on this site.
The tracker grew to eighteen. U.S. News published debut ratings for GLP-1 telehealth platforms (2026–27), and seven rated platforms weren’t in our field — they are now, at the only tier honesty allows on day one: Amazon One Medical, Fridays, Ivim Health, LifeMD, Noom Med, PlushCare, and WeightWatchers Clinic, each with a structural profile, a diligence script, and a queue position (#11–#17) in the public verification protocol. Ratings are visibility; our rows fill with checkout-verified numbers or they don’t fill.
Method note. Every claim above is attributed and dated because that’s the deal this site makes with volatile facts: FDA and CMS pages control their own programs, our changelog records what we change, and the ledger’s verified/pending split stays the spine. What did not change: no invented prices, no pay-to-rank, and the named-medical-reviewer upgrade remains in progress rather than faked.
Corrections welcome — the channel pays.